Yan Lu

Yan Lu

Auto-generated profile, based on publicly available information

Yan Lu

Key Laboratory of Integrative Biomedicine for Brain Diseases, Center for Translational Systems Biology and Neuroscience, Nanjing University of Chinese Medicine, Nanjing, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2012 in Virology
Verified
Journal Article
Closed access
CHCheng-Qiang He
Cheng-Qiang He
NDNai-Zheng Ding
Nai-Zheng Ding
XMXue Mou
Xue Mou
ZXZhixun Xie
Zhixun Xie
HONGLI SIHONGLI SI
HONGLI SI
RCRun-Nan Cao
Run-Nan Cao

27 October 2021 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
YZYuxuan Zhang
Yuxuan Zhang
BCBo Cui
Bo Cui
TWTianyu Wang
Tianyu Wang
YLYan Lu
Yan Lu
ZCZhenlin Chen
Zhenlin Chen
GCGang Chen
Gang Chen
Background: Current mainstream treatment of major depressive disorder (MDD) has a disadvantage in delayed onset of efficacy, making detection of early signatures predicative of the long-term treatment efficacy urgent.Methods: MDD patients were scored with HAMD-24 and serum brain-derived neurotrophic factor (BDNF) levels were measured at different times in two independent trials: a single-arm observation of Yueju pill, a clinically approved traditional multiherbal medicine, and a two-arm random placebo-controlled trial for Yueju vs escitalopram. The ratio of the BDNF level to HAMD-24 score, or neuroplasticity index (NI), and its derived parameters were used for correlation analysis and receiver operating characteristic (ROC) analysis.Results: On both the early (4th) and final (28th) days, Yueju and escitalopram significantly reduced HAMD-24 scores, compared to baselines, but only Yueju increased BDNF at both times. For either Yueju or escitalopram treatment, NI, but not BDNF, at baseline was correlated to NIs at the early or final treatment day. NI at early time was significantly correlated to early NI enhancement from the baseline for both Yueju and escitalopram, and to final NI enhancement from the baseline for Yueju in both trials. ROC analysis supported the predictability of Yueju’s final treatment efficacy from early NI enhancement.Limitations: The small sample size and 28 days of treatment time may lead to the impossibility of ROC analysis of escitalopram.Conclusion: Early NI enhancement is useful for prediction of long-term efficacy of Yueju and presumably some other antidepressants.Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [ChiCTR1900021114].

15 May 2023 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
ZHZhen Hu
Zhen Hu
NZNing Zhao
Ning Zhao
YLYan Lu
Yan Lu